Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Rosén

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2017
Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of LifeBradley E Chipps, Tmirah Haselkorn, Karin Rosén, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2016
A randomized multicenter study evaluating Xolair persistence of response after long-term therapyDennis Ledford, William Busse, Benjamin Trzaskoma, et al.
Clinical and Translational Allergy|August 20, 2016
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studiesAna M Gimenéz-Arnau, Sheldon Spector, Evgeniya Antonova, et al.
The Journal of Allergy and Clinical Immunology|October 21, 2015
Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticariaAllen Kaplan, Marta Ferrer, Jonathan A Bernstein, et al.
The New England Journal of Medicine|February 26, 2013
Omalizumab for the treatment of chronic idiopathic or spontaneous urticariaMarcus Maurer, Karin Rosén, Hsin-Ju Hsieh, et al.
The Journal of Allergy and Clinical Immunology|April 1, 2014
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabAidan Long, Abdelkader Rahmaoui, Kenneth J Rothman, et al.
American Journal of Respiratory and Critical Care Medicine|March 9, 2013
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA studyNicola A Hanania, Sally Wenzel, Karin Rosén, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 10, 2015
Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background TherapyThomas B Casale, Jonathan A Bernstein, Marcus Maurer, et al.
The Journal of Investigative Dermatology|July 22, 2014
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled studySarbjit S Saini, Carsten Bindslev-Jensen, Marcus Maurer, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2013
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyAllen Kaplan, Dennis Ledford, Mark Ashby, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2017
Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of LifeBradley E Chipps, Tmirah Haselkorn, Karin Rosén, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2016
A randomized multicenter study evaluating Xolair persistence of response after long-term therapyDennis Ledford, William Busse, Benjamin Trzaskoma, et al.
Clinical and Translational Allergy|August 20, 2016
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studiesAna M Gimenéz-Arnau, Sheldon Spector, Evgeniya Antonova, et al.
The Journal of Allergy and Clinical Immunology|October 21, 2015
Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticariaAllen Kaplan, Marta Ferrer, Jonathan A Bernstein, et al.
The New England Journal of Medicine|February 26, 2013
Omalizumab for the treatment of chronic idiopathic or spontaneous urticariaMarcus Maurer, Karin Rosén, Hsin-Ju Hsieh, et al.
The Journal of Allergy and Clinical Immunology|April 1, 2014
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabAidan Long, Abdelkader Rahmaoui, Kenneth J Rothman, et al.
American Journal of Respiratory and Critical Care Medicine|March 9, 2013
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA studyNicola A Hanania, Sally Wenzel, Karin Rosén, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 10, 2015
Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background TherapyThomas B Casale, Jonathan A Bernstein, Marcus Maurer, et al.
The Journal of Investigative Dermatology|July 22, 2014
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled studySarbjit S Saini, Carsten Bindslev-Jensen, Marcus Maurer, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2013
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyAllen Kaplan, Dennis Ledford, Mark Ashby, et al.
Pageof 1